Can breastfeeding women use semaglutide injection?
Regarding the use of semaglutide injection (Wegovy) in lactating women, there is currently a lack of systematic clinical data. Animal studies have shown that the drug can be detected in the milk of rats injected with Semaglutide, suggesting that it may be secreted into breast milk. Although there is no direct evidence for the presence of semaglutide or its metabolites in human milk and no adverse effects on nursing infants have been observed, the potential risks should be considered with caution.

Clinically, when breastfeeding mothers use semaglutide, the mother's health status, the necessity of using the drug, and the benefits of breastfeeding to the baby should be comprehensively evaluated. If the mother has obvious obesity or metabolic risk, and semaglutide is a necessary treatment, the pros and cons need to be weighed under the guidance of a doctor, and she may consider suspending breastfeeding or choosing an alternative. During this process, the baby's health and weight development are regularly monitored to ensure the safety of the drug.
Guidelines recommend that lactating women should be cautious with any long-term use of medications, especially newGLP-1 receptor agonists. Parents and medical staff should fully understand the drug's mechanism of action, possible risks of breast milk transfer, and potential effects, and develop a usage plan based on individualized treatment needs. In the future, more clinical studies on the use of semaglutide during lactation will help clarify safety and guide clinical practice.
In summary, the use of semaglutide injection by lactating women is still within the scope of caution. It is necessary to comprehensively assess the maternal needs and infant safety, follow the guidance of professional physicians, and ensure a balance between weight loss treatment and breastfeeding. For most breastfeeding mothers, it is recommended to delay use or choose an alternative in non-emergency situations to ensure the safety of mother and baby.
Reference materials:https://www.drugs.com
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)